Accordingly, guidance endorses nutritional vitamin D as the base strategy to correct deficiency while avoiding mega-bolus dosing (≥100,000 IU) and excessive 25(OH)D; active VD/VDRAs are not for routine prevention in CKD G3–G5 (CKD stages 3–5) off dialysis but reserved for progressive/severe SHPT(secondary hyperparathyroidism) or PTH control on dialysis (95, 96). This evidence concerns the gene PTH and chronic kidney disease.